Mind Medicine (MindMed) Inc. [NASDAQ: MNMD] jumped around 0.01 points on Tuesday, while shares priced at $3.18 at the close of the session, up 0.32%. The company report on July 12, 2021 that MindMed Chosen to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
– MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that MindMed’s Chief Executive Officer, Robert Barrow, will be leading a roundtable discussion at Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit.
The event is set to take place on July 13th, 2021 from 4:15-5:00pm ET. A live audio webcast of the presentation will be available in the “Investors” section on MindMed’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit mindmed.co/investor-resources/.
Mind Medicine (MindMed) Inc. stock is now 4.26% up from its year-to-date (YTD) trading value. MNMD Stock saw the intraday high of $3.2191 and lowest of $3.11 per share. The company’s 52-week high price is 5.77, which means current price is +55.12% above from all time high which was touched on 04/27/21.
Compared to the average trading volume of 11.31M shares, MNMD reached a trading volume of 2550311 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Mind Medicine [MindMed] Inc. [MNMD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MNMD shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MNMD stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Mind Medicine (MindMed) Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 28, 2021.
The Average True Range (ATR) for Mind Medicine (MindMed) Inc. is set at 0.21
How has MNMD stock performed recently?
Mind Medicine (MindMed) Inc. [MNMD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.19. With this latest performance, MNMD shares dropped by -14.97% in over the last four-week period, additionally plugging by 5.77% over the last 6 months – not to mention a rise of 901.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MNMD stock in for the last two-week period is set at 42.03, with the RSI for the last a single of trading hit 37.03, and the three-weeks RSI is set at 45.29 for Mind Medicine (MindMed) Inc. [MNMD]. The present Moving Average for the last 50 days of trading for this stock 3.42, while it was recorded at 3.22 for the last single week of trading, and 2.74 for the last 200 days.
Mind Medicine [MindMed] Inc. [MNMD]: Deeper insight into the fundamentals
Return on Total Capital for MNMD is now -79.31, given the latest momentum, and Return on Invested Capital for the company is -86.40. Return on Equity for this stock declined to -86.40, with Return on Assets sitting at -83.88.
Insider trade positions for Mind Medicine [MindMed] Inc. [MNMD]
There are presently around $1 million, or 0.78% of MNMD stock, in the hands of institutional investors. The top three institutional holders of MNMD stocks are: TRU INDEPENDENCE LLC with ownership of 167,293, which is approximately 48.45% of the company’s market cap and around 5.72% of the total institutional ownership; GOFEN & GLOSSBERG LLC /IL/, holding 72,500 shares of the stock with an approximate value of $0.23 million in MNMD stocks shares; and FNY INVESTMENT ADVISERS, LLC, currently with $0.13 million in MNMD stock with ownership of nearly 106.5% of the company’s market capitalization.
Positions in Mind Medicine (MindMed) Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 13 institutional holders increased their position in Mind Medicine (MindMed) Inc. [NASDAQ:MNMD] by around 183,158 shares. Additionally, 1 investors decreased positions by around 1,000 shares, while 2 investors held positions by with 206,693 shares. The mentioned changes placed institutional holdings at 390,851 shares, according to the latest SEC report filing. MNMD stock had 10 new institutional investments in for a total of 96,601 shares, while 1 institutional investors sold positions of 1,000 shares during the same period.